Difference between revisions of "Volunteer Assignments and Opportunities"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
VisualWikitext
[unchecked revision][unchecked revision]
Line 148: Line 148:
 
|
 
|
 
|-
 
|-
−
|Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms||'''''Overview'''''|| ||Example
+
|Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms||'''''Overview'''''|| ||Jennelle Hodge (JH)
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||'''''Overview'''''|| ||Example
+
|Myeloid Neoplasms with Germline Predisposition||'''''Overview'''''|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Acute Myeloid  Leukaemia with Germline CEBPA Mutation||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Myeloid Neoplasms  with Germline DDX41 Mutation||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Myeloid Neoplasms  with Germline RUNX1 Mutation||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Myeloid Neoplasms  with Germline ANKRD26 Mutation||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Myeloid Neoplasms  with Germline ETV6 Mutation||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Myeloid Neoplasms  with Germline GATA2 Mutation||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Acute Myeloid Leukemia (AML) with Recurrent Genetic  Abnormalities||'''''Overview'''''|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Acute Myeloid  Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Acute Myeloid  Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Acute Promyelocytic  Leukemia (APL) with PML-RARA||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Acute Myeloid  Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Acute Myeloid  Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Acute Myeloid  Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Acute Myeloid  Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Acute Myeloid  Leukemia (AML) with BCR-ABL1||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Acute Myeloid  Leukemia (AML) with Mutated NPM1||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Acute Myeloid  Leukemia (AML) with Biallelic Mutations of CEBPA||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Acute Myeloid  Leukemia (AML) with Mutated RUNX1||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Therapy-Related Myeloid Neoplasms||Disease|| ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example|| || ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example|| || ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example|| || ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example|| || ||JH
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example|| || ||Example
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example|| || ||Example
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Example||Example|| ||Example
+
|Example|| || ||Example
 
|
 
|
 
|
 
|

Revision as of 17:16, 21 May 2020

Disease Page Type Author Associate Editor Author Content (Pending or Complete) Editor Reviewed (Date)
Myeloproliferative Neoplasms (MPN) Overview Fabiola Quintero-Rivera (FQR)
Chronic Myeloid Leukemia (CML), BCR-ABL1-Positive Disease FQR
Chronic Neutrophilic Leukemia (CNL) Disease FQR
Polycythaemia Vera (PV) Disease FQR
Primary Myelofibrosis (PMF) Disease FQR
Essential Thrombocythaemia (ET) Disease FQR
Chronic Eosinophilic Leukemia, Not Otherwise Specified Disease FQR
Myeloproliferative Neoplasm (MPN), Unclassifiable Disease FQR
Mastocytosis Overview FQR
Cutaneous Mastocytosis Disease FQR
Systemic Mastocytosis Disease FQR
Mast Cell Sarcoma Disease FQR
Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2 Overview FQR
Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement Disease FQR
Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement Disease FQR
Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement Disease FQR
Myeloid/Lymphoid Neoplasms with PCM1-JAK2 Disease FQR
Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) Overview FQR
Chronic Myelomonocytic Leukemia (CMML) Disease FQR
Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative Disease FQR
Juvenile Myelomonocytic Leukemia (JMML) Disease FQR
Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) Disease FQR
Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable Disease FQR
Myelodysplastic Syndromes (MDS) Overview FQR
Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia Disease FQR
Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS) Disease FQR
Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia Disease FQR
Myelodysplastic syndrome with multilineage dysplasiaMyelodysplastic Syndrome (MDS) with Multilineage Dysplasia Disease FQR
Myelodysplastic Syndrome (MDS) with Excess Blasts Disease FQR
Myelodysplastic Syndrome (MDS) with Isolated del(5q) Disease FQR
Myelodysplastic Syndrome (MDS), Unclassifiable Disease FQR
Refractory Cytopenia of Childhood Disease FQR
Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms Overview Jennelle Hodge (JH)
Myeloid Neoplasms with Germline Predisposition Overview JH
Acute Myeloid Leukaemia with Germline CEBPA Mutation Disease JH
Myeloid Neoplasms with Germline DDX41 Mutation Disease JH
Myeloid Neoplasms with Germline RUNX1 Mutation Disease JH
Myeloid Neoplasms with Germline ANKRD26 Mutation Disease JH
Myeloid Neoplasms with Germline ETV6 Mutation Disease JH
Myeloid Neoplasms with Germline GATA2 Mutation Disease JH
Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities Overview JH
Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 Disease JH
Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 Disease JH
Acute Promyelocytic Leukemia (APL) with PML-RARA Disease JH
Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3 Disease JH
Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214 Disease JH
Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM Disease JH
Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1 Disease JH
Acute Myeloid Leukemia (AML) with BCR-ABL1 Disease JH
Acute Myeloid Leukemia (AML) with Mutated NPM1 Disease JH
Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA Disease JH
Acute Myeloid Leukemia (AML) with Mutated RUNX1 Disease JH
Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes Disease JH
Therapy-Related Myeloid Neoplasms Disease JH
Example JH
Example JH
Example JH
Example JH
Example Example
Example Example
Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Example Example Example
Retrieved from "https://ccga.io/index.php?title=Volunteer_Assignments_and_Opportunities&oldid=7924"